OTCM
HAVLF
Market cap48kUSD
Dec 04, Last price
0.00USD
1D
90.00%
1Q
90.00%
IPO
-99.73%
Name
HAVN Life Sciences Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
-100.00%
Net income
0k
P
CFO
0k
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds. The company was incorporated in 2020 and is headquartered in Richmond, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑04 | 2022‑04 | 2021‑04 | 2020‑04 | |
| Income | ||||
Revenues | ||||
Cost of revenue | ||||
Unusual Expense (Income) | ||||
NOPBT | ||||
NOPBT Margin | ||||
Operating Taxes | ||||
Tax Rate | ||||
NOPAT | ||||
Net income | ||||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | ||||
BB yield | ||||
| Debt | ||||
Debt current | ||||
Long-term debt | ||||
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | ||||
| Cash flow | ||||
Cash from operating activities | ||||
CAPEX | ||||
Cash from investing activities | ||||
Cash from financing activities | ||||
FCF | ||||
| Balance | ||||
Cash | ||||
Long term investments | ||||
Excess cash | ||||
Stockholders' equity | ||||
Invested Capital | ||||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | ||||
Price | ||||
Market cap | ||||
EV | ||||
EBITDA | ||||
EV/EBITDA | ||||
Interest | ||||
Interest/NOPBT | ||||